Medpace Holdings Reports Q1 Earnings, Shares Move Lower

Comments
Loading...
Zinger Key Points

Medpace Holdings Inc MEDP reported first-quarter financial results after market close on Monday. Here’s a look at the key metrics from the quarter.

  • Q1 Revenue: $558.57 million, versus estimates of $527.15 million
  • Q1 EPS: $3.67, versus estimates of $3.06

Total revenue was up 9.3% on a year-over-year basis. New business awards totaled $500 million in the quarter, down 18.8% year-over-year. The company ended the period with a backlog of approximately $2.85 billion, down 2.1% year-over-year.

Medpace generated $125.8 million in cash flow from operations during the quarter. The company said it repurchased approximately 1.19 million shares for $389.8 million in the first quarter. Medpace’s board also authorized a $1 billion increase to the company’s buyback, bringing the total authorization up to approximately $1.34 billion.

The company ended the quarter with $441.4 million in cash and cash equivalents.

Outlook: Medpace expects full-year 2025 revenue to be between $2.14 billion and $2.24 billion versus estimates of $2.15 billion. The company anticipates full-year earnings of $12.26 to $13.04 per share versus estimates of $12.27 per share.

Medpace executives will further discuss the quarter on a call with investors and analysts Tuesday morning at 9 a.m. ET.

MEDP Price Action: Medpace shares were down 9.34% after-hours, trading at $262 at the time of publication Monday, according to Benzinga Pro.

Check This Out:
• Calix Stock Jumps On Strong Q1 Earnings, $100 Million Buyback Increase

Photo: mariakray/Shutterstock.

MEDP Logo
MEDPMedpace Holdings Inc
$284.79-1.45%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
28.15
Growth
72.13
Quality
93.15
Value
19.79
Price Trend
Short
Medium
Long
Got Questions? Ask
Which clinical research firms might benefit from MEDP's performance?
How will Medpace's share buyback impact investor sentiment?
Could decreased new business awards affect MEDP's growth strategy?
What implications does Medpace's cash flow have for future investments?
How could Medpace's earnings outlook influence competitor stocks?
Which biotech companies could be affected by Medpace's earnings?
Will increased buyback authorization help stabilize MEDP's stock?
How might Medpace's operational cash flow attract institutional investors?
What sectors might see increased demand following Medpace's results?
Which healthcare ETFs could benefit from Medpace's performance?
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In: